PCT/US 99/06700
IPEA/US 05 JUN 2000

We claim:

1. A method for treating HIV infections comprising administering a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

2. The method of Claim 1 further comprising administering more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

3. The method of Claim 1 further comprising administering more than one integrase inhibitor.

4. The method of Claim 2 further comprising administering more than one integrase inhibitor.

5. The method of Claim 1, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

PCT/US 99/06700
IPEA/US 05 JUN 2000

6. The method of Claim 1, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

7. The method of Claim 1, wherein the protease inhibitor is Nelfinavir.

8. A composition for treating HIV infections comprising a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

9. The composition of Claim 8, wherein the integrase inhibitor is selected from a group consisting of chicoric acid, 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

10. The composition of Claim 8, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

PCT/US 99/06700
IPEA/US 05 JUN 2000

11. The composition of Claim 8, wherein the protease inhibitor is Nelfinavir.

12. The composition of Claim 8 further comprising more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

13. The composition of Claim 8 further comprising more than one integrase inhibitor.

14. The composition of Claim 12 further comprising more than one integrase inhibitor.

15. An integrase inhibitor selected from a group consisting of 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

16. An integrase inhibitor having the formula:



wherein n is between 0 and 4;

wherein R_2 and R_4 are hydrogen

wherein R_1 and R_3 are selected from the group consisting of hydrogen, OR_6, NR_6 and aralkyl groups;

wherein R_6 is



wherein X is a hydrocarbyl group with from 0 to 10 carbon atoms, Y is selected from CH=CH, N=CH, CH=N, O, S, or NR_7. m is between 0 and 3, and R_8 is selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, alkycarbonyloxy and alkoxycarbonyloxy or a cyclic carbonate group with hydroxy groups on adjacent carbons; and

wherein R and R_5 are selected from the group consisting of hydrogen, $COOR_7$ and $CONHR_7$;

wherein R_7 is selected from the group consisting or hydrogen, alkyl and aralkyl; and

wherein when R and R_5 are $COOR_7$ and R_7 is hydrogen and R_1 and R_3 are OR_6, then R_6 and R_8 are hydroxy, m is not 2 and X and Y are not CH=CH.

17. The integrase inhibitor of Claim 16, wherein R_2 and R_4 combine with each other to form a cycloalkyl ring.

18. The integrase inhibitor of Claim 16, wherein R_2 and R_4 are combined with R_1 and R_4, respectively, to form aromatic rings.

19. The integrase inhibitor of Claim 18, wherein the aromatic rings are substituted with from one to three substituents selected from OR_6 and NR_6 groups.

20. The integrase inhibitor of Claim 16, wherein when R and R_5 are $COOR_7$ or $CONHR_7$, and R_1, R_2 and R_3, R_4 combine to form an arylidene group.

21. The integrase inhibitor of Claim 20, wherein the arylidene group is substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, halo, alkoxy, alkycarbonyloxy and alkoxycarbonyloxy.

22. An integrase inhibitor having the formula:



wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises an amino acid linked by an ester or amide bond.

23. An integrase inhibitor having the formula:



wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises a chain of between 1 and 6 carbon atoms.